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ABSTRACT: The possible reason for the significantly greater AUC of oral warfarin with oral
oxolamine in male SpragueDawley rats was evaluated. After oral administration of warfarin at a
dose of 2 mg/kg to male rats with oxolamine at doses of 10 and 50 mg/kg, the AUC values of
warfarin were significantly greater than the controls (254 and 330 versus 180 mg h/ml). However,
the AUC values of warfarin were not affected by oxolamine in female rats. This could be due to
inhibition of CYP2B1, 2C11 and 3A2 by oxolamine in male rats, since warfarin was metabolized via
CYP1A1, 2B1, 2C6, 2C11 and 3A2 in rats and CYP2B1 is male dominant, and CYP2C11 and 3A2 are
male specific. Therefore, phenytoin, torasemide and clarithromycin (mainly metabolized via
CYP2B1/2, 2C11 and 3A2 in rats, respectively) were administered intravenously to male rats with
or without oral oxolamine. After oral oxolamine at doses of 10 and 50 mg/kg, the AUC of phenytoin
was significantly greater (1280 and 1640 versus 938 mg min/ml), however, the AUC values of
torasemide and clarithromycin were independent of oxolamine. The above data suggest that the
significantly greater AUC of oral warfarin with oral oxolamine could be due to inhibition of
CYP2B1/2 by oxolamine in male rats. Copyright # 2007 John Wiley & Sons, Ltd.
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Introduction
Gender differences in the pharmacokinetics of
drugs could be due to the differences in the
following factors: the gastric emptying rate,
intestinal transit time, gut enzyme, body water
space, muscle mass, organ blood flow rate, organ
function, body fat and hepatic metabolism,
between men and women [1]. Among the factors,
differences in the hepatic microsomal cyto-
chrome P450 (CYP) systems play a significant
role in the gender differences [1].
Warfarin is widely used as a coumarin antic-
oagulant with a narrow therapeutic index requir-
ing a tight control in dosage regimen.
Commercially available warfarin is a racemic
mixture of (R)- and (S)-enantiomers. The racemic
warfarin is metabolized via the CYP1A2, 2C9 and
3A4 in humans [2], and the CYP1A1, 2B1, 2C6,
2C11 and 3A2 in rats [3]. It was reported that rat
CYP1A1, 1A2, 2B1, 2C11 and 3A1 and human
CYP1A1, 1A2, 2B6, 2C9 and 3A4 proteins have
78%, 70%, 74%, 77% and 73% homology, respec-
tively [4]. Hence, the CYP isozymes responsible
for the metabolism of racemic warfarin are
similar between rats and humans. In this regard,
rats could be used as an animal model in order to
study pharmacokinetic changes of warfarin. Rat
CYP2B1 is male dominant, CYP2C11 and 3A2 are
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male specific, and CYP1A1 and 2C6 have no
gender difference [4]. However, studies on
the human CYP isozyme do not seem to have
been published. In humans, the clearance,
volume of distribution, half-life, urinary
excretion, plasma protein binding and extent
of absolute oral bioavailability (F) of warfarin
are 0.045 0.024 ml/min/kg, 0.14 0.06 l/kg,
37 15 h, less than 2%, 99 1% and 93 8%,
respectively [5]. It was reported that there was a
gender difference in the pharmacokinetics of oral
warfarin in rats; the total area under the plasma
concentration–time curve from time zero to
time infinity (AUC) of oral warfarin at a dose of
2 mg/kg in male SpragueDawley rats was
significantly smaller (47.8% decrease) than
that in female rats [6]. However, a gender
difference in the pharmacokinetic parameters of
warfarin in humans does not seem to have been
published.
Oxolamine [3-phenyl-5-(b-diethyloaminoethyl)-
1,2,4-oxadiazole] citrate is an antiinflammatory
agent with a particular antitussive activity.
Therefore, it has been used extensively in
hospitals for patients with coughs. Oxolamine is
also being prescribed to patients who are stable
on warfarin therapy. However, the types of CYP
isozymes that are inhibited by oxolamine do not
seem to have been published yet.
In the anticoagulation services (ACS) in Korean
Hospitals (Seoul National University Hospital,
Seoul, and Samsung Medical Center, Seoul,
Republic of Korea), drug interaction between
warfarin and oxolamine has been observed; the
international normalized ratio (INR) of warfarin
increased in patients coadministered with oxola-
mine. Similar results were also reported in six
male and five female patients [7]. This suggests
that the anticoagulant activity of warfarin was
increased by oxolamine. Although pharmacoki-
netic interactions between warfarin and numer-
ous drugs with respect to CYP isozyme changes
have been reported [8], a pharmacokinetic inter-
action between warfarin and oxolamine does not
seem to have been published. Hence, rats were
used as an animal model in order to find a
pharmacokinetic interaction between warfarin
and oxolamine in patients.
The purpose of this study was to report the
possible reason for the gender difference in the
AUC of oral warfarin (significantly greater AUC
of oral warfarin coadministered with oral oxola-
mine to male rats) in terms of possible inhibition
of warfarin metabolism by oxolamine via
CYP2B1/2 in male rats.
Materials and methods
Chemicals
Oxolamine citrate and torasemide were donated
from Dongsung Pharmaceutical Company
(Seoul, Republic of Korea) and Roche Pharma-
ceutical Company (Manheim, Germany), respec-
tively. Warfarin, 7-ethoxycoumarin (an internal
standard for high-performance liquid chromato-
graphic, HPLC, analysis of warfarin), tris(hy-
droxymethyl) aminomethane (Tris1)-buffer,
phenytoin and chlorozoxazone (an internal stan-
dard for HPLC analysis of torasemide and
phenytoin) were purchased from Sigma–Aldrich
Corporation (St Louis, MO). Clarithromycin and
roxithromycin (an internal standard of HPLC
analysis of clarithromycin) were supplied from
Research Laboratory of Dong-A Pharmaceutical
Company (Yongin, Republic of Korea).
Other chemicals were of reagent grade or HPLC
grade.
Animals
Male (weighing 250–320 g) and female (weighing
190–260 g) SpragueDawley rats of 6–8 weeks of
age were purchased from Samtako Bio Korea
(Seoul, Republic of Korea). All rats were main-
tained in a clean room (Animal Center for
Pharmaceutical Research, College of Pharmacy,
Seoul National University, Seoul, Republic of
Korea) at a temperature of between 20 and 23 8C
with a 12 h light (0700–1900) and dark (1900–
0700) cycle and a relative humidity of 50%. Rats
were housed in metabolic cages (Tecniplast,
Varese, Italy) under a supply of filtered patho-
gen-free air with food (Samyang Company,
Pyeongtaek, Republic of Korea) and water ad
libitum. They were fasted overnight before the
experiment. The protocol of the animal study
was approved by Animal Care and Use Commit-
tee of College of Pharmacy of Seoul National
University.
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Oral administration of warfarin to male and
female rats pretreated with or without oxolamine
Oxolamine citrate (dissolved in distilled water) at
doses of 10 and 50 mg/kg as the oxolamine base
were administered orally (oral volume of 5 ml/kg)
using a feeding tube for 3 consecutive days (3 times
per day) to male and female rats. The same volume
of distilled water was administered to control rats.
The procedures for the pretreatment of rats
including the cannulation of the carotid artery
(for blood sampling) were similar to previously
reported methods [9]. The carotid artery was
cannulated with a polyethylene tube (Clay
Adams, Parsippany, NJ) under light ether an-
esthesia on day 4 after the oral administration of
oxolamine or distilled water (control rats). The
cannula was exteriorized to the dorsal side of the
neck, where the cannula was terminated with a
long silastic tube (Dow Corning, Midland, MI).
The silastic tube was covered with a wire sheath
to allow free movement of the rats. They were not
restrained during the whole experimental period.
A heparinized 0.9% NaCl-injectable solution
(approximately 0.3 ml; 15 unit/ml) was used to
flush the cannula to prevent blood clotting. Each
rat was housed individually in a metabolic cage
(Daejong Scientific Company, Seoul, Republic of
Korea) and allowed to recover from anesthesia
for 4–5 h before the commencement of the
experiment. On day 4 just after oral administra-
tion of oxolamine or distilled water, warfarin
(dissolved in distilled water) at a dose of 2 mg/
kg was administered orally (total oral volume of
1.5 ml) to male rats (n ¼ 10, 10 and 10 for control
rats and rats pretreated with oxolamine at doses
of 10 and 50 mg/kg, respectively) and female rats
(n ¼ 10, 10 and 9 for control rats and rats
pretreated with oxolamine at doses of 10 and
50 mg/kg, respectively). An approximately
0.22 ml aliquot of blood sample was collected
via the carotid artery in an Eppendorf tube at 0
(to serve as a control), 0.5, 1, 2, 4, 8, 12, 24, 36, 48
and 72 h after oral administration of warfarin. An
approximately 0.3 ml aliquot of the heparinized
0.9% NaCl-injectable solution (20 unit/ml) was
used to flush each cannula immediately after
each blood sampling. Blood samples were cen-
trifuged (HST-8 Centrifuge; Hanil Science Indus-
trial Company, Seoul, Republic of Korea)
immediately, and a 100ml aliquot of each plasma
sample was stored in a 70 8C freezer (Model
DF8517; Ilshin Laboratory Company, Seoul, Repub-
lic of Korea) until HPLC analysis of warfarin [10].
Intravenous administration of phenytoin, torase-
mide or clarithromycin to male rats pretreated
with or without oxolamine
On day 4 just after oral administration of
oxolamine, phenytoin (at a dose of 25 mg/kg;
dissolved in distilled water with a minimum
amount of 10n NaOH), mainly metabolized via
CYP2B1 in rats [11], torasemide (at a dose of
2.5 mg/kg; dissolved in distilled water with a
minimum amount of 10n NaOH and adjusted to
a final pH of approximately 8 with Tris-HCl),
mainly metabolized via CYP2C11 in rats [12], or
clarithromycin (at a dose of 20 mg/kg; dissolved
in 0.9% NaCl-injectable solution by adding few
drops of 85% phosphoric acid), mainly metabo-
lized via CYP3A2 in rats [13] was infused (total
injection volume of 2 ml/kg for each drug) for
1 min via the jugular vein of male rats. The
numbers of male rats used were 8, 8 and 7 for
control rats and rats pretreated with oxolamine at
doses of 10 and 50 mg/kg, respectively, for
phenytoin, and the corresponding values for
torasemide and clarithromycin were 9, 10 and
10, and 8, 9 and 10. The blood sampling time
schedules for phenytoin [11], torasemide [12] and
clarithromycin [13] were the same as previously
reported methods. The other procedures were
similar to the above mentioned warfarin studies.
Measurement of Vmax, Km and Clint for the
disappearance of warfarin or phenytoin in hepatic
microsomal fractions
The procedures are similar to the reported methods
[14]. The livers of rats without (control) or with oral
oxolamine at doses of 10 and 50 mg/kg (n ¼ 6, 5
and 5 for warfarin and n ¼ 6, 4 and 5 for phenytoin,
respectively) were homogenized (Ultra-Turrax T25;
Janke and Kunkel, IKA-Labortechnik, Staufeni,
Germany) in an ice-cold buffer of 0.154m KCl/
50 mm Tris-HCl in 1 mm EDTA, pH 7.4. The
homogenate was centrifuged at 10 000 g for
30 min and the supernatant fraction was further
centrifuged at 100 000 g for 90 min. The
protein content was measured using the reported
INHIBITION OF WARFARIN METABOLISM BY OXOLAMINE VIA CYP2B1 IN MALE RATS 127
Copyright # 2007 John Wiley & Sons, Ltd. Biopharm. Drug Dispos. 28: 125–133 (2007)
DOI: 10.1002/bdd
method [15]. The Vmax (the maximum velocity) and
Km (the Michaelis–Menten constant; the concentra-
tion at which the rate is one-half of Vmax) for the
disappearance of warfarin or phenytoin were
determined after incubating the above microsomal
fractions (equivalent to 0.5 mg), a 5ml aliquot of
distilled water that contained 1, 5, 10, 50 and 100mm
of warfarin or distilled water with a minimum
amount of 10 n NaOH that contained 1, 2.5, 5, 10, 20
and 50mm of phenytoin and a 50ml aliquot of Tris-
HCl buffer, pH 7.4 that contained 1 mm of NADPH
in a final volume of 0.5 ml by adding 0.1 m
phosphate buffer, pH 7.4, in a water-bath shaker
kept at 37 8C and at a rate of 500 oscillations per min
(opm). All the above microsomal incubation condi-
tions were linear. The reaction was terminated by
the addition of a 1 ml aliquot of diethyl ether after
15 min incubation for phenytoin or 30 min incuba-
tion for warfarin. Warfarin [10] or phenytoin [16]
was measured by the reported HPLC method. The
kinetic constants (Km and Vmax) for the disappear-
ance of warfarin or phenytoin were calculated
using the nonlinear regression method [17]. The
intrinsic clearance (Clint) for the disappearance of
warfarin or phenytoin was calculated by dividing
the respective Vmax by the respective Km.
Measurement of plasma protein binding of
clarithromycin
Protein binding of clarithromycin at a concentra-
tion of 10 mg/ml with or without oxolamine at a
concentration of 10 mg/ml to fresh rat plasma of
control rats (n ¼ 4, each) was determined using
the equilibrium dialysis technique [18]. One ml of
plasma was dialysed for 24 h at 37 8C against 1 ml
of isotonic Srensen phosphate buffer of pH 7.4
that contained 3% (w/v) dextran in a 1 ml
dialysis cell (Spectrum Medical Industries,
Los Angeles, CA) using a Spectra/Por 4 mem-
brane (mol. wt cutoff of 12 000–14 000 Da, Spec-
trum Medical Industries). After 24 h incubation,
two 100 ml aliquots were collected from each
compartment and stored in a 70 8C freezer until
HPLC analysis of clarithromycin [19].
HPLC analysis of warfarin, phenytoin, torase-
mide and clarithromycin
The concentrations of warfarin [10], phenytoin
[16], torasemide [12] and clarithromycin [19] in
plasma sample were analysed by the reported
HPLC methods.
Pharmacokinetic analysis
The AUC was calculated using the trapezoidal
rule–extrapolation method; this method employs
the logarithmic trapezoidal rule for the calcula-
tion of the area during the phase of a declining
plasma level phase [20] and the linear trapezoi-
dal rule for the phase of a rising level in plasma.
The area from the last datum point to the infinity
was estimated by dividing the last measured
concentration in plasma by the terminal-phase
rate constant.
Standard methods [21] were used to calculate
the following pharmacokinetic parameters using
the noncompartmental analysis (WinNonlin 2.1;
Pharsight Corp., Mountain View, CA); the first
moment of AUC (AUMC), terminal half-life,
mean residence time (MRT), apparent volume
of distribution at steady state (Vss), and time-
averaged total body clearance (Cl). The peak
plasma concentration (Cmax) and time to reach a
Cmax (Tmax) were read directly from the experi-
mental data.
The harmonic mean method was used to
calculate the mean values of Vss [22], terminal
half-life [23] and Cl [24].
Statistical analysis
A value of p50.05 was considered to be
statistically significant using a Duncan’s multiple
range test of Statistical Package for Social
Sciences (SPSS) posteriori analysis of variance
(ANOVA) among the three means for the
unpaired data or an unpaired t-test. All data
are expressed as mean  standard deviation.
Results
Pharmacokinetics of warfarin after oral adminis-
tration of warfarin to male and female rats with
or without oral oxolamine
After oral administration of warfarin at a dose
of 2 mg/kg to male and female rats pretreated
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with or without oxolamine at doses of 10 and
50 mg/kg, the mean arterial plasma concentra-
tions–time profiles of warfarin are shown in
Figure 1, and some relevant pharmacokinetic
parameters are listed in Table 1. In male rats, the
AUC values of warfarin with oxolamine at doses
of 10 and 50 mg/kg were significantly greater
(41.1% and 83.3% increase, respectively) than the
controls; each value was significantly different. In
male rats, the terminal half-lives of warfarin with
oxolamine at doses of 10 and 50 mg/kg were
significantly longer (50.3% and 75.2% increase,
respectively) than the controls; the values were
not significantly different between oxolamine at
doses of 10 and 50 mg/kg. However, in female
rats, the pharmacokinetic parameters of warfarin
listed in Table 1 were not significantly different
among the three groups of rats.
Pharmacokinetics of phenytoin, torasemide and
clarithromycin with or without oral oxolamine
After intravenous administration of each drug to
male rats pretreated with or without oxolamine,
the mean arterial plasma concentrations–time
profiles of phenytoin, torasemide and clarithro-
mycin are shown in Figure 2, and some relevant
pharmacokinetic parameters are listed in Table 2.
After intravenous administration of phenytoin to
rats pretreated with oxolamine at a dose of
50 mg/kg, the AUC of phenytoin was signifi-
cantly greater (74.8% increase) than the controls.
After intravenous administration of phenytoin to
rats with oxolamine at doses of 10 and 50 mg/kg,
the Cl of phenytoin was significantly slower
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Figure 1. Mean arterial plasma concentration–time profiles of
warfarin after oral administration of warfarin at a dose of
2 mg/kg without (*; n ¼ 10; for both male and female rats) or
with oral oxolamine at doses of 10 (&; n ¼ 10; for both male
and female rats) and 50 (*; n ¼ 10 and 9 for male and female
rats, respectively) mg/kg three times per day for 3 con-
secutive days to male (a) and female (b) rats. Bars represent
standard deviation
Table 1. Mean ( standard deviation) pharmacokinetic
parameters of warfarin after oral administration of warfarin
at a dose of 2 mg/kg without (control) or with oral oxolamine
at doses of 10 and 50 mg/kg to male and female rats
Oxolamine
Parameter Control 10 mg/kg 50 mg/kg
Male ðn ¼ 10Þ ðn ¼ 10Þ ðn ¼ 10Þ
AUC (mg h/ml) 180 52.0a 254 112 330 53.7
Cmax (mg/ml) 7.13 3.12 8.42 2.38 8.95 2.61
Tmax (h) 6.50 3.69 6.90 3.60 9.05 10.1
Terminal half-life (h) 16.1 5.43b 24.2 8.65 28.2 6.89
Female ðn ¼ 10Þ ðn ¼ 10Þ ðn ¼ 9Þ
AUC (mg h/ml) 345 80.0 395 92.8 333 89.2
Cmax (mg/ml) 7.53 1.29 9.66 3.66 7.62 1.17
Tmax (h) 11.6 4.79 13.0 3.66 8.06 6.56
Terminal half-life (h) 28.4 8.32 24.9 14.1 30.1 7.05
a Each value was significantly different (p50.05).
b Control was significantly different (p50.05) from oxolamine, 10 and
50 mg/kg.
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the controls. However, the pharmacokinetic
parameters of torasemide listed in Table 2 were
not significantly different among the three
groups of rats. The pharmacokinetic parameters
of clarithromycin listed in Table 2 were also
not significantly different among the three
groups of rats except for a significantly larger
Vss (96.9% increase) and significantly faster Cl
(107% increase) with oxolamine at a dose of
50 mg/kg and a considerably smaller AUC
(30.8% decrease; p50.1) of clarithromycin than
the controls.
Measurement of Vmax, Km and Clint for the
disappearance of warfarin or phenytoin in rat
liver microsomes
The Vmax, Km and Clint for the disappearance of
warfarin or phenytoin in hepatic microsomal
fractions of the three groups of rats are listed in
Table 3. In rats pretreated with oral oxolamine at
doses of 10 and 50 mg/kg, the Vmax for the
disappearance of warfarin was considerably
slower (24.8% and 32.8% decrease, respectively)
and the Vmax for the disappearance of phenytoin
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Figure 2. Mean arterial plasma concentration–time profiles of phenytoin (a), torasemide (b) and clarithromycin (c) after
intravenous administration at a dose of 25 (phenytoin), 2 (torasemide) and 20 (clarithromycin) mg/kg without (*; n ¼ 8, 9 and 7
for phenytoin, torasemide and clarithromycin, respectively) or with oxolamine at doses of 10 (&; n ¼ 8, 10 and 9 for phenytoin,
torasemide and clarithromycin, respectively) or 50 (*; n ¼ 7, 9 and 10 for phenytoin, torasemide and clarithromycin,
respectively) mg/kg three times per day for 3 consecutive days to male rats. Bars represent standard deviation
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(60.2% and 52.4% decrease, respectively) was
significantly slower than the controls, suggesting
that maximum velocity for the disappearance
(mainly due to metabolism) of warfarin or
phenytoin was slower after oxolamine. However,
the Km values for both the disappearance of
warfarin and phenytoin were not significantly
different between the three groups of rats,
suggesting that the affinity of warfarin or
phenytoin to the enzyme(s) was not changed in
rats pretreated with oral oxolamine. Hence, the
Clint for the disappearance of warfarin (32.2%
and 29.7% decrease for warfarin, respectively) or
phenytoin (49.4% and 33.4% decrease, respec-
tively) in rats with oral oxolamine at doses of 10
and 50 mg/kg was significantly slower than the
controls. This suggests that in rats pretreated
with oxolamine at doses of 10 and 50 mg/kg, the
metabolism of warfarin or phenytoin decreased
compared with the controls.
Table 2. Mean ( standard deviation) pharmacokinetic parameters of phenytoin, torasemide and clarithromycin after
intravenous administration at doses of 25, 2, and 20 mg/kg, respectively, without (control) or with oral oxolamine at doses of 10
and 50 mg/kg to male rats
Oxolamine
Parameter Control 10 mg/kg 50 mg/kg
Phenytoin ðn ¼ 8Þ ðn ¼ 8Þ ðn ¼ 7Þ
AUC (mg min/ml) 938 182a 1280 327 1640 806
Terminal half-life (min) 39.3 42.1 39.3 32.3 62.4 49.0
MRT (min) 41.8 24.4 39.5 23.9 60.1 34.1
Vss (ml/kg) 806 823 617 694 865 249
Cl (ml/min/kg) 25.4 5.00b 19.5 3.98 15.3 6.48
Torasemide ðn ¼ 9Þ ðn ¼ 10Þ ðn ¼ 10Þ
AUC (mg min/ml) 1640 441 1670 362 1520 252
Terminal half-life (min) 115 26.0 115 18.5 105 18.8
MRT (min) 104 22.9 95.7 19.0 94.5 20.5
Vss (ml/kg) 126 8.02 115 4.61 123 13.9
Cl (ml/min/kg) 1.22 0.301 1.19 0.277 1.32 0.245
Clarithromycin ðn ¼ 8Þ ðn ¼ 9Þ ðn ¼ 10Þ
AUC (mg min/ml) 328 157c 293 58.0 227 61.5
Terminal half-life (min) 121 32.7 121 41.7 147 51.6
MRT (min) 95.3 20.9 95.1 42.3 106 43.0
Vss (ml/kg) 3810 3070
a 5590 3890 7500 5740
Cl (ml/min/kg) 42.6 30.3a 68.3 18.6 88.2 25.3
a Control was significantly different (p50.05) from oxolamine, 50 mg/kg.
b Control was significantly different (p50.05) from oxolamine, 10 and 50 mg/kg.
c Control was considerably different (p50.1) from oxolamine, 50 mg/kg.
Table 3. Mean ( standard deviation) Vmax, Km and Clint for the disappearance of warfarin or phenytoin by microsomes
prepared from livers of rats without (control) or with oral oxolamine at doses of 10 and 50 mg/kg
Oxolamine
Parameter Control 10 mg/kg 50 mg/kg
Warfarin ðn ¼ 6Þ ðn ¼ 5Þ ðn ¼ 5Þ
Vmax (nmol/min/mg protein) 3.16 0.795
a 2.37 0.539 2.12 0.852
Km (mm) 104 36.5 117 39.4 98.6 26.1
Clint (ml/min/mg protein) 0.0312 0.00398
b 0.0212 0.00493 0.0219 0.00749
Phenytoin ðn ¼ 6Þ ðn ¼ 4Þ ðn ¼ 5Þ
Vmax (nmol/min/mg protein) 1.24 0.493
b 0.492 0.507 0.588 0.180
Km (mm) 34.117.4 20.2 11.0 22.1 6.18
Clint (ml/min/mg protein) 0.0396 0.0113
b 0.0201 0.014 0.0264 0.00110
a Control was considerably different (p50.1) from oxolamine, 10 and 50 mg/kg.
b Control was significantly different (p50.05) from oxolamine, 10 and 50 mg/kg.
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Plasma protein binding of clarithromycin
Plasma protein binding values of clarithromycin
with or without oxolamine were 51.9  2.24%
and 43.5  4.56%, respectively; they were
significantly different (p50.05).
Discussion
It was reported that statistically significant
correlations between the log pharmacokinetic
parameters of warfarin (half-life, metabolic clear-
ance, volume of distribution, intrinsic clearance
of unbound drug and unbound volume of
distribution of tissues) and the log body weight
were obtained from rats and humans [25].
Moreover, the CYP isozymes responsible for the
metabolism of racemic warfarin between humans
[2] and rats [5] were similar. Hence, rats were
chosen as an animal model in the present study.
In male rats, the AUC values of oral warfarin
pretreated with oral oxolamine at both doses
were significantly greater than the controls
(Table 1). This could be supported by signifi-
cantly slower Clint of warfarin by oxolamine
(Table 3). However, in female rats, the AUC
values of warfarin were not significantly differ-
ent, regardless of oxolamine pretreatment
(Table 1). This gender difference in the changes
of AUC values of oral warfarin with oral
oxolamine suggests that oxolamine may inhibit
CYP2B1, 2C11 and/or 3A2, since warfarin is
metabolized via CYP1A1, 2B1, 2C6, 2C11 and
3A2 in rats [2], and CYP2B1 is male dominant,
CYP2C11 and 3A2 are male specific, CYP1A2 is
female dominant, but CYP1A1 and 2C6 have no
gender difference in rats [4].
Hence, phenytoin, torasemide and clarithro-
mycin were intravenously administered to male
rats with or without oxolamine to find which
CYP isozymes are inhibited by oxolamine in
male rats. It was reported that torasemide is
mainly metabolized via CYP2C11 in male rats
[12]. Hence, torasemide at a dose of 2 mg/kg was
administered intravenously to male rats pre-
treated with oxolamine to find whether oxola-
mine can inhibit CYP2C11 in rats. However, the
AUC values of torasemide were not significantly
different in male rats between control and
oxolamine-pretreated groups (Table 2), suggest-
ing that oxolamine does not seem to inhibit
considerably CYP2C11 in male rats. It was also
reported that clarithromycin was mainly meta-
bolized via CYP3A1/2 in male rats [13]. Hence,
clarithromycin at a dose of 20 mg/kg was
administered intravenously to male rats pre-
treated with oxolamine to find whether oxola-
mine can inhibit CYP3A1/2 in rats. However, the
AUC value of clarithromycin was considerably
smaller (p50.1) with oxolamine at a dose of
50 mg/kg than the controls (Table 2). If oxola-
mine can inhibit CYP3A1/2, the AUC of clari-
thromycin could be greater than the controls. The
above data suggest that oxolamine does not seem
to inhibit considerably CYP3A1/2 in male rats.
Although, the exact reason is not clear, the
significantly larger Vss of clarithromycin in the
oxolamine (50 mg/kg)-pretreated group could be
due to significantly greater free (unbound to
plasma proteins) fractions of the drug in plasma;
the free fraction of clarithromycin with oxola-
mine was significantly greater (17.3% increase)
than that of without oxolamine. It was obtained
recently from our laboratories that 40-hydroxy-
lated phenytoin (40-HPPH) was formed from
phenytoin mainly via the CYP2C9 and 2C11
and the metabolism of phenytoin to other
metabolites was mediated via CYP2B1/2 in male
SpragueDawley rats (our unpublished data).
Similar results were also reported in rats [26,27].
Hence, phenytoin at a dose of 25 mg/kg was
administered intravenously to male rats pre-
treated with oxolamine to find whether oxola-
mine can inhibit CYP2B1/2 in male rats. The
AUC of phenytoin was significantly greater in
rats pretreated with oxolamine (Table 2) than the
controls, suggesting that the oxolamine can
inhibit CYP2B1/2 in male rats. This can be
supported by the significantly slower Clint in rats
pretreated with oxolamine (Table 3).
The gender-different pharmacokinetics of war-
farin does not seem to have been published in
humans before. It was reported that human
CYP2B6 is not male dominant [28].
In conclusion, the gender difference in the
significantly greater AUC values of oral warfarin
with oral oxolamine in male rats could be due to
an inhibition of metabolism of warfarin via
CYP2B1/2 by oxolamine.
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